At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 267 enrolled
Drug / intervention
Nilotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In Brief
A Phase 3 clinical trial evaluating Nilotinib and Imatinib for Chronic Myeloid Leukemia. Completed, enrolled 267 participants across 12 sites.
Detailed Summary
The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukemia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartApr 2011
Primary CompletionOct 2014
TodayJul 2026
First PostedJan 12, 2011
Enrollment StartApr 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 15.5 years ago
Interventions
Nilotinibdrug
Imatinibdrug